Antitumor strategies targeting macrophages: the importance of considering the differences in differentiation/polarization processes between human and mouse macrophages

Marine Monnier,1,2 Léa Paolini,1,2 Emeline Vinatier,1,2,3 Alberto Mantovani4,5,6, Yves Delneste,1,2,3 Pascale Jeannin1,2,3

ABSTRACT
Macrophages are the immune cells that accumulate the most in the majority of established tumors and this accumulation is associated with a poor prognosis. Tumor-associated macrophages (TAMs) produce inflammatory cytokines and growth factors that promote tumor expansion and metastasis. TAMs have recently emerged as targets of choice to restore an efficient antitumor response and to limit tumor growth. Many molecules targeting TAMs are actually evaluated in clinical trials, alone or in combination. While these molecules induce tumor regression and stimulate cytotoxic responses in mouse models of tumor development, results from early clinical trials are less impressive. In this review, we list the biological differences between human and mouse macrophages that help explain the different efficacy of antitumor strategies targeting TAMs between human and animal studies. Differences in the impact of survival and polarization factors and in the cytokines produced and markers expressed as well as the limitations of extrapolations based on in vitro models of TAM-like generation should be considered in order to improve the design and efficacy of antitumor drugs targeting TAMs.

INTRODUCTION
Macrophages, which are the most abundant infiltrating immune cells in the majority of solid tumors, facilitate tumor growth and metastasis. Indeed, tumor-associated macrophages (TAMs) participate in most of the mechanisms involved in tumor growth, namely cell proliferation, angiogenesis, metastasis, immune suppression and smoldering inflammation. TAMs have thus emerged as targets and different strategies, such as functional reprogramming or inhibition of their recruitment, gave encouraging results in several preclinical models of tumor development. Nevertheless, the results in humans may be less impressive. Considering the biological differences between human and mouse macrophages and the limits of the models and markers used to assess their functions should improve the design and effectiveness of antitumor strategies based on targeting/manipulating TAMs. In this review, we highlight the differences between human and murine TAMs (summarized in table 1) that need to be considered in the design of clinical trials.

MACROPHAGES, A HETEROGENEOUS AND MULTIFUNCTIONAL CELL POPULATION
Macrophages are myeloid cells of the innate immune system, present in almost all tissues. They perform diverse and essential functions. In addition to their antimicrobial activity, they ensure the maintenance of tissue homeostasis and control all phases of healing and tissue repair. They are also involved in the initiation and resolution of the inflammation and can present antigens to memory (but not naive) T cells.

Resident macrophages exhibit highly specialized functions (eg, Kupffer cells in the liver or microglia in the central nervous system). Monocytes can also be recruited to inflamed or injured tissues, where they undergo local differentiation into macrophages. This process is a critical step in their functional polarization, as the phenotype they acquire is driven by the nature of the differentiation signals present in their environment. Moreover, macrophages are plastic, meaning that they continuously adapt their phenotype to the demands of the tissue, as they permanently screen their environment. A multitude of factors/signals, such as microbes, cytokines, changes in nutrients or metabolite...
### Table 1  Differences between mouse and human macrophages that may impact the efficacy of antitumor strategies targeting TAM

| Parameters                        | Murine Mφ                                                                 | Human Mφ                                                                 | Tumor microenvironment and human TAMs                                      | Therapeutic implications                                                                 |
|----------------------------------|---------------------------------------------------------------------------|--------------------------------------------------------------------------|----------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
| Roles of GM-CSF                  | Induces DCs and Mφ generation                                              | Induces Mφ generation                                                    | Present in inflammatory and tumor sites                                       | M-CSF neutralization may boost the impact of GM-CSF and thereby favor DC generation in mice but not in human |
| Type II IFN expression           | High expression                                                           | Low expression by both in vitro generated human Mφ and TAMs             |                                                                             | Type II IFN production by murine TAMs may favor cytotoxic T lymphocyte responses and their reprogramming into antitumor Mφ |
| M1/M1-type versus M2/M2-type polarizing factors | M1: IFNγ+LPS, M-CSF+IFNγ                                                   | M1-type: GM-CSF, GM-CSF+IFNγ, M-CSF+IFNγ                                 | Cancers are mostly infiltrated by Th1, Th17 and Treg cells rather than Th2 cells | The M1/M2 model is not relevant for human TAM characterization                            |
|                                  | M2: M-CSF+IL-4                                                            | M2-type: M-CSF+IL-4 (or IL-1 or IL-10)                                   |                                                                             |                                                                                          |
| M1/M1-type and M2/M2-type markers | M1: iNOS, CD80, MHC-II, IFNγ                                               | M1-type: inflammatory cytokines (IL-1β, IL-6 and TNFα), IL-12            | Human TAMs exhibit both M1 and M2 characteristics (concomitant expression of inflammatory and regulatory cytokines and of growth factors) | Prototypic mouse M1 and M2 markers cannot be used to characterize human TAMs             |
|                                  | M2: Arg1, Ym1, VEGF ...                                                   | M2-type: growth factors (TGF-β, VEGF, EGF, PDGF), IL-10                  |                                                                             |                                                                                          |
| Polarization versus activation   | Resting (M2) and LPS-stimulated (M1) cells are usually compared            | Human Mφ and TAMs require to be stimulated (such as via CD40 or TLRs) to reveal their phenotypes |                                                                             | Human Mφ polarization and activation are two independent processes                         |

Arg1, arginase 1; DCs, dendritic cells; EGF, epithelial growth factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; iNOS, inducible nitric oxide synthase; LPS, lipopolysaccharide; M-CSF, macrophage colony-stimulating factor; MHC-II, major histocompatibility complex class II; Mφ, macrophage; PDGF, platelet-derived growth factor; PRR, pattern recognition receptors; TAMs, tumor-associated macrophages; TGF-β, transforming growth factor-β; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.
and their accumulation is associated, in most cancers, with a poor prognosis. TAMs favor tumor growth and metastasis, angiogenesis and lymphangiogenesis and tumor-associated inflammation, and decrease effector CD8+ T-cell recruitment and function (Figure 1).

TAMs derive from both resident tissue macrophages and newly recruited monocytes. In a mouse model of lung cancer, lineage tracing experiments revealed that TAMs are initially composed of resident macrophages that acquire protumor functions and proliferate, and that, in later phases of tumor development, TAMs are predominantly composed of recruited monocytes that have differentiated locally. While the proliferation of murine macrophages has been widely reported, that of human macrophages remains poorly documented.

In humans, the importance of monocyte recruitment in maintaining pools of TAMs was recently demonstrated in patients with cancer after bone marrow transplantation. Moreover, it appears obvious that the density of TAMs in a fast-growing tissue may probably result from the recruitment of monocytes rather than a massive expansion of resident macrophages whose proliferative capacity remains questionable in humans.

Many molecules targeting TAMs are currently in clinical trials, either alone or in combination with chemotherapy, radiotherapy or immunotherapy (especially immune checkpoint inhibitors (ICI)). TAM-targeting approaches, described in recent reviews, are of two types: those preventing TAM accumulation and/or survival (eg, by inhibiting the macrophage colony-stimulating factor (M-CSF)/CD115 or C-C motif chemokine ligand 2 (CCL2)/CCR2 axis) and those making use of the phagocytic properties of TAMs (eg, blocking the SIRP1α/CD47 interaction) or of their cytotoxic activity. These strategies decrease tumor growth and stimulate cytotoxic CD8+ T-cell responses in combination with chemotherapy, radiotherapy, or ICI in different mouse models of tumor development. Based on these results, clinical trials aiming to evaluate the impact of strategies targeting TAMs are currently underway. Here, we provide an overview of some of the key observations that need to be considered when extrapolating results obtained in mouse models to humans.

**Differences in the processes of generation and functional polarization of mouse and human macrophages**

Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces the generation of dendritic cells in mice and macrophages in humans

As discussed earlier, the accumulation of TAMs in established tumors results principally from monocyte recruitment induced by attracting molecules, including mainly M-CSF (CSF-1) and CCL2 (also known as MCP-1). This process can be also induced by other chemokines, such as CX-C chemokine receptor type 4 (CXCR4) and CXCR5 ligands. A number of clinical trials are assessing neutralization of CD115 (or c-fms), the receptor for M-CSF and interleukin (IL)-34, as a means of preventing TAM accumulation. In mouse models, neutralization

**TAMS: A COMPLEX DIVERSITY**

In the majority of established tumors, macrophages accumulate in larger numbers than the other immune cells, and their accumulation is associated, in most cancers, 10x10 Open access

Monnier M, et al. J Immunother Cancer 2022;10:e005560. doi:10.1136/jitc-2022-005560
of the M-CSF–IL-34/CD115 axis acts in synergy with chemotherapy and ICI to reduce tumor growth and to favor CD8⁺ T-cell responses.²⁶³⁴ However, clinical trials in humans have given disappointing results³⁵ and some TAM subsets seem resistant to this approach.²⁵ It also seems likely that in vivo neutralization of the M-CSF–IL-34/CD115 axis amplifies the impact of GM-CSF (also known as CSF-2) on myeloid cells.³⁶

Importantly, GM-CSF has different effects on myeloid cell differentiation in human and mice.³⁷ M-CSF is constitutively expressed in many tissues, whereas GM-CSF is present principally at sites of inflammation, including tumor sites, as it is produced by activated immune and non-immune cells and by some tumors.³⁷⁻³⁹ GM-CSF triggers the differentiation of murine myeloid precursors into mature dendritic cells,⁴⁰⁴¹ and favors antitumor responses by facilitating dendritic cell recruitment and activation.³⁷⁴² For example, in a murine melanoma model, vaccination with irradiated melanoma cells engineered to secrete GM-CSF stimulates robust and long-lasting anti-tumor immunity.⁴³⁴⁴ Conversely, GM-CSF neutralization affects murine dendritic cell recruitment in vivo.⁴⁵ Based on these observations, GM-CSF has been used in dendritic cell-based tumor vaccine trials as an inducer of dendritic cell maturation, and is currently included in antitumor immunotherapies.⁴² However, in humans, both M-CSF and GM-CSF promote monocyte survival and differentiation into macrophages (figure 2A, left panel). M-CSF triggers in vitro the generation of regulatory macrophages that maintain tissue homeostasis, whereas GM-CSF induces the generation of macrophages that produce inflammatory cytokines (including IL-6, IL-1β) and tumor necrosis factor (α) on stimulation (figure 2B), the production of these mediators being upregulated by interferon.

**Figure 2** Differences in the generation and polarization of human and murine macrophages. (A) Left panel, human macrophages are usually generated in vitro from peripheral blood monocytes cultured in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) (in the presence or absence of IFNγ) or macrophage colony-stimulating factor (M-CSF)/interleukin (IL)-34 (in the presence or absence of IL-4) to generate M1 and M2 cells, respectively. To reveal their phenotype, human macrophages must be activated. Right panel: Murine macrophages are primarily generated from bone marrow myeloid cell progenitors maintained in M-CSF. The use of GM-CSF leads to the generation of both dendritic cells and macrophages.⁸⁷ (B) Left panel, human markers of macrophage polarization are shown. Right panel: murine markers of macrophage polarization. BMDC, bone-marrow derived dendritic cells; BMDM, bone-marrow derived macrophages; HIF-1α, hypoxia inducible factor; IFNg, Interferon-gamma; IRF, Interferon regulatory factor; LPS, lipopolysaccharide; MHC-II, major histocompatibility complex class II; STAT, Signal transducer and activator of transcription.
gamma (IFNγ). Moreover, high concentrations of GM-CSF promote the recruitment of immunosuppressive murine myeloid cells within tumors. This, and the opposite effects of GM-CSF on the differentiation of human and murine myeloid precursors into macrophages and dendritic cells, respectively, may provide some explanation for the poor efficacy of GM-CSF as an adjuvant for antitumor vaccines in humans.

Importantly, a recent study reported, in a mouse model of breast-to-brain metastasis, that the inhibition of CD115 induced a compensatory increase of GM-CSF synthesis by pericytes that induced the acquisition by TAM of an inflammatory and tissue repair profile. One can thus suspect that, in vivo, the neutralization of the M-CSF–IL-34/CD115 axis may exacerbate the role of GM-CSF, which would then promote the generation, in humans, of inflammatory macrophages favoring tumor recurrence.

Moreover, we have recently shown that the simultaneous presence of GM-CSF and lactic acid, a metabolite that accumulates in glycolytic tumors, induces the generation of macrophages producing inflammatory cytokines and tumor-promoting factors that display similarities to the ovarian cancer TAMs. Another study also reported that lactic acid increases the expression of VEGF by murine macrophages. These results suggest that some features of TAMs are induced independently of M-CSF, a prototypic M2 inducer, contributing to explain the lack of sensitivity to CD115 blockade of some TAM subsets, such as angiogenic TAMs.

It could be argued that, in the presence of IL-4 and/or IL-13, GM-CSF induces the differentiation of human monocytes into dendritic cells. While lactic acid is frequently found in cancers, the expression of IL-4 or IL-13 has only been reported in a restricted number of cancers, and mouse, but not human myeloid cells, express IL-4 and IL-13, excluding an autocrine role in the generation of human TAMs. Collectively, these results suggest that the role of IL-4 and IL-13 in the functional polarization of human TAM should be limited.

It should be noted that other strategies aiming to reduce macrophage accumulation by neutralizing the CCL2/CCR2, CXCL12 (or SDF1)/CXCR4 or IL-1/IL-1 receptor axes, together with strategies reducing the recruitment of neutrophil precursors, which exhibit suppressive properties (eg, by targeting the C5a receptor, by jointly neutralizing CCR2 and CCR5, or by using a CD11b agonist), are also currently evaluated in clinical trials.

Given the difference in factors controlling dendritic cell and macrophage generation between humans and mice, the impact of these strategies on the recruitment and differentiation of precursor(s) and/or activation of human macrophages (as well as of dendritic cells) should systematically be evaluated.

Polarization and activation of human macrophages should be distinguished as two independent processes

Macrophages express different phenotypes, depending on the signals present in the environment. In vitro experiments with human monocytes have shown that this process, referred to as polarization, is time dependent. Moreover, human macrophages require stimulation (via CD40 or using TLR agonists) to reveal their cytokine profile (except those constitutively produced, such as CCL2). For murine M1 and M2 cells, the terms polarization and activation are not dissociated, and resting and activated cells are compared in studies using murine cells. Myeloid cell activators, including TLR agonists, are currently evaluated in clinical trials as inducers of TAM reprogramming into antitumor cells. Importantly, TLR9 is expressed by murine but not human myeloid cells, a fundamental difference that may profoundly impact the consequences of TLR9 agonists on macrophage polarization.

TLRs and CD40 agonists induce dendritic cell maturation and facilitate the generation of a protective antitumor response. In contrast, the activation of TAM is likely to enhance the production of immunosuppressive cytokines and growth factors, thus strengthening their protumor phenotype. Thus, acting on both polarization and activation may be required to reprogram human TAMs into antitumor cells. Repolarization could be achieved by modulating the metabolic and/or cytokine microenvironment. Consistent with the view of tumors as a wound that never heals, we and others have shown that factors classically associated with tissue lesions, such as lactic acid, contribute to the phenotype of TAMs.

Various molecules affecting tumor cell metabolism (by inhibiting glycolysis or other metabolic pathways) are currently in clinical trials; the impact of these molecules, used alone or, preferentially, in combination with other TAM-targeting molecules, should also be studied on human TAMs. Combination treatments that repolarize TAMs and activate TAMs and dendritic cells should be beneficial.

**Phenotypic differences between human and mouse macrophages/TAMs**

**Mouse and human macrophages differ in their capacity to produce IFNγ**

IFNγ, which has an important role in immune surveillance, facilitates the generation and activation of Th1 lymphocytes and the initiation of cytotoxic T lymphocyte responses. IFNγ is also a potent activator of myeloid cells: it polarizes dendritic cells into IL-12-producing cells (known as DC1), thereby facilitating the generation of Th1 lymphocytes. Previously known as macrophage activating factor, IFNγ induces the generation of inflammatory macrophages that are potentially cytotoxic to tumor cells. IFNγ may also have protumor effects through a feedback effect. For example, IFNγ helps to maintain peripheral tolerance by increasing PD-L1 expression by tumor cells.

Due to its potent antitumor activity, IFNγ has been used in the treatment of certain cancers and is currently being tested, in association with other antitumor molecules, in clinical trials. It is currently thought that the
dose and duration of IFNγ treatment need to be established, to optimize its beneficial effect when combined with antitumor therapies. Nevertheless, while murine macrophages are IFNγ-producing cells (figure 2B, right panel), human myeloid cells produce IFNγ at a very low level compared with lymphoid cells. and, importantly, the combination IL-12 plus IL-18 appears as the most effective in inducing IFNγ production by human macrophages. Of note, IL-12, a prototypic antitumor cytokine, is poorly expressed in most tumors and IL-18 exhibits protumor activity (favoring cancer progression, metastasis, angiogenesis and immune suppression). This will make unlikely an in situ reprogramming of human TAM into antitumor cells in the absence of IFNγ-producing lymphoid cells. Moreover, the activation/reprogramming by IFNγ may lower the efficacy of anti-PD-1/-PD-L1 antibody treatment (consecutive to an upregulation of PD-L1 expression by tumor cells), in contrast to the beneficial impact of combining TAM activation (that induces IFNγ production) and PD1 targeting in murine models of tumor development.

The M1/M2 model does not reflect the phenotypic diversity of TAMs

Murine TAMs are commonly characterized by transcriptome analysis, thanks to the specific expression of genes defined as ‘M2/protumor’ and ‘M1/antitumor’ cells, according to the M1/M2 classification which distinguishes macrophages differentiated in the presence of M-CSF with either IL-4 (M2) or IFNγ plus LPS (M1) (figure 2A, right panel).

Although IL-4 and IL-13 expressions have been detected in some cancers, the use of macrophages generated in the presence of IL-4 as a model for protumor macrophages is of little physiological relevance, as discussed earlier. The M1/M2 classification was based on the Th1/Th2 dichotomy, itself derived from an analysis of the physiological mechanisms associated with autoimmune diseases in mice of different genetic backgrounds. The pathophysiology of autoimmune diseases is now characterized by a Th1–Th17/Treg imbalance rather than a Th1/Th2 imbalance. Similarly, cancer development is associated with a sustained inflammation and profound immune suppression involving Th1, Th17 and Treg cells, rather than Th2 accumulation. Moreover, although the expression of IL-4 and IL-13 has been detected in some cancers, M2 cells generated in the presence of IL-4 are considered as prototypic tissue repair macrophages rather than bona fide protumor macrophages.

Macrophages play an essential role in controlling all stages of the tissue repair process, but the expression of IL-4 or IL-13 is not a characteristic of healing areas, and other factors present locally in the injured areas, such as IL-21, IL-25 and IL-33, may also confer a wound healing phenotype to macrophages. Thus, the study of genes associated with M2 cells generated in the presence of IL-4 are of more relevance in mouse models of allergic reactions or helminth infections than in cancers or wound-healing process.

Most of the prototypic murine M1 and M2 markers are not suitable for the characterization of human macrophages

The phenotypes of macrophage subsets drastically differ between human and mouse (figure 2B). Human M1-like macrophages are characterized by an elevated expression of membrane CD80 and CD86 and by the secretion of inflammatory cytokines and IL-12. In contrast, murine M1 macrophages express CD11c, CD11b and CD38 and produce nitric oxide in addition to proinflammatory cytokines. Human M2-like macrophages are characterized by an elevated expression of CD163 and CD206 and by the production of IL-10 and of several growth factors when murine M2 macrophages are defined as arginase 1 (Arg1)-expressing and VEGF-expressing cells. Moreover, the genes overexpressed in the presence of IL-4 or IFNγ greatly differ between human and mouse macrophages. Either there are no human homologs of particular genes (eg, Ym1 and Fizz1) or their expression is differentially regulated. The most widely used signature is the expression of inducible nitric oxide synthase by murine M1 cells and of Arg1 by murine M2 cells, two molecules not expressed by human macrophages.

More generally, there is little correspondence between the genes upregulated by IL-4 in human and mouse macrophages. In addition, most of the genes used to characterize murine M1 and M2 cells have no known function, making it difficult to extrapolate their protumor versus antitumor functions. Reinforcing this result, Zilionis et al nicely demonstrated that, in lung tumors, TAMs exhibit species-specific profiles, emphasizing the importance of characterizing human macrophages instead of extrapolating from mouse phenotypes. Finally, the transcription factors involved in the polarization of M1-like and M2-like macrophages differ between human and mouse (figure 2B).

The most informative and reliable way to characterize the function of human macrophages is based on the profiling of soluble mediators, including growth factors, inflammatory cytokines and immunosuppressive molecules. This approach is all the more relevant as cumulative single-cell analysis studies in different tumors revealed/confirmed that human TAM exhibit mixed M1-like and M2-like signatures. Surface markers on human macrophages display lower levels of modulation than cytokine production, and, when modulated (eg, CD163, which reflects M-CSF consumption; CD206, which reflects IL-4 consumption), their expression is not predictive of their protumor or antitumor functions.

Concluding remarks

In conclusion, the different impacts of GM-CSF on human versus murine myeloid cell differentiation, the absence of IFNγ and TLR9 expression by human macrophages and the limits of models using IL-4 as an inducer of repair macrophages are all features that distinguish human
macrophages from mouse macrophages and that must be considered when translating from the preclinical to the clinical therapeutic application.

All these information have to be taken account to optimize strategies that directly target TAM, especially with the emergence of promising new antitumor therapies that promote the phagocytic activity of macrophages by targeting the CD47/SIRPα axis, as recently reported for B-cell lymphoma and some solid tumors.\(^\text{83-86}\)

**Correction Notice** This article has been corrected. The affiliations of Alberto Mantovani have been updated.

**Contributors** PJ conceived and supervised this study, MM and LP drafted the manuscript and the figures. AM and YD provided critical revision of the manuscript. All authors read and approved the submitted version.

**Funding** This study did not receive specific grant from funding agencies in the public, commercial, or not-for-profit sectors. This work was realized in the context of (i) the LabEx ImmunoGraffOnco program (National Research Agency; ANR-11- LABX-0016-01) and (ii) the University Hospital of Angers - University of Angers joint program (3I-Impact).

**Competing interests** None declared.

**Patient consent for publication** Not applicable.

**Ethics approval** Not applicable.

**Provenance and peer review** Commissioned; externally peer reviewed.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iD**
Alberto Mantovani http://orcid.org/0000-0001-5578-236X

**REFERENCES**

1. Gomez-Roca CA, Italiano A, Le Tourneau C, et al. Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages. *Ann Oncol* 2019;30:1381–92.

2. Noel M, O'Reilly EM, Wolpin BM, et al. Phase 1B study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PP-01436308) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. *Invest New Drugs* 2020;38:800–11.

3. Lucas T, Waisman A, Ranjan R, et al. Differential roles of macrophages in diverse phases of skin repair. *J Immunol* 2010;184:3984–77.

4. Okabe Y, Medzhitov R. Tissue biology perspective on macrophages. *Nat Rev Drug Discov* 2010;9:53–70.

5. Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. *Nat Med* 2015;21:938–45.

6. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. *J Clin Invest* 2012;122:787–95.

7. Bindea G, Miecznik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. *Immunity* 2013;39:782–95.

8. Thorsson V, Gibbis DL, Brown SD, et al. The immune landscape of cancer. *Immunity* 2019;51:411–2.

9. Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. *Nat Rev Drug Discov* 2018;17:887–904.

10. Sinha VC, Rinkenbaugh AL, Xu M, et al. Single-cell evaluation reveals shifts in the tumor-immune niches that shape and maintain aggressive lesions in the breast. *Nat Commun* 2021;12:5024.

11. Mantovani A, Marches F, Malessi A, et al. Tumour-associated macrophages as treatment targets in oncology. *Nat Rev Clin Oncol* 2017;14:399–416.

12. Allavena P, Sica A, Garlanda C, et al. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. *Immunol Rev* 2008;222:155–61.

13. Lorenzani A, Soffani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. *Trends Immunol* 2002;23:549–55.

14. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. *Immunity* 2014;41:49–61.

15. Loyer P-L, Hamroun P, Laviron M, et al. Macrophages of distinct origins contribute to tumor development in the lung. *J Exp Med* 2018;215:2536–53.

16. Casanova-Acebes M, Dalla E, Leader AM, et al. Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells. *Nature* 2021;595:578–84.

17. Hashimoto D, Chow A, Noizat C, et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. *Immunity* 2013;38:792–804.

18. Klein I, Cornejo JC, Polakos NK, et al. Kupffer cell heterogeneity: functional properties of bone marrow derived and sessile hepatic macrophages. *Blood* 2007;110:4077–85.

19. Chorro L, Sarde A, Li M, et al. Langerhans cell (LC) proliferation mediates neonatal development, homeostasis, and inflammation-associated expansion of the epidermal LC network. *J Exp Med* 2009;206:3089–100.

20. Zhang L, Li Z, Skrzypczynska KM, et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. *Cell* 2020;181:e29:442–59.

21. Wang J, Wang Y, Chu Y, et al. Tumor-derived adenosine promotes macrophage proliferation in human hepatocellular carcinoma. *J Hepatol* 2021;74:627–37.

22. Yang N, Isbel NM, Nikolic-Paterson DJ, et al. Local macrophage proliferation in human gliomereulonephropathy. *Kidney Int* 1998;54:143–51.

23. Kurashige M, Kohara M, Onshima K, et al. Origin of cancer-associated fibroblasts and tumor-associated macrophages in humans after sex-mismatched bone marrow transplantation. *Commun Biol* 2018;1:131.

24. Anfray C, Urrmanno A, Andón FT, et al. Current strategies to target tumor-associated-macrophages to improve anti-tumor immune responses. *Cells* 2019;9:doi:10.3390/cells9010046. [Epub ahead of print: 23 12 2019].

25. Lin Y, Xu J, Lan H. Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. *J Hepatol Oncol* 2019;12:76.

26. Kowal J, Kornete M, Joyce JA. Re-education of macrophages as a therapeutic strategy in cancer. *Immunotherapy* 2019;11:677–89.

27. Pittet MJ, Michieli O, Migliorini D. Clinical relevance of tumor-associated macrophages. *Nat Rev Clin Oncol* 2022;19:402–21.

28. Piechutta M, Berghoff AS. New emerging targets in cancer immunotherapy: the role of cluster of differentiation 40 (CD40/ TNFR5). *ESMO Open* 2019;4:e000510.

29. Takimoto CH, Chao MP, Gibbs C, et al. The Macrophage 'Do not eat me' signal, CD47, is a clinically validated cancer immunotherapy target. *Ann Oncol* 2019;30:486–9.

30. Jail AR, Andrechak JC, Discher DE. Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRPα structure-function. *Antib Ther* 2020;3:80–94.

31. Zhang W, Huang Q, Xiao W, et al. Advances in anti-tumor treatments targeting the CD47/SIRPα axis. *Front Immunol* 2020;11:18.

32. Peranzoni E, Lemoine J, Vimeux L, et al. Phase Ib study of the combination of pasidittarin (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors. *Ther Adv Med Oncol* 2019;11:1785835919854238.

33. Pradel LF, Olt C-H, Romagnoli S, et al. Macrophage susceptibility to Emactuzumab (RG7155) treatment. *Mol Cancer Ther* 2016;15:3077–86.

34. Jeannin P, Paolinli L, Adam C, et al. The roles of CSFs on the functional polarization of tumor-associated macrophages. *Febs J* 2018;285:680–99.

35. Hamilton JA, Cook AD, Tak PP. Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases. *Nat Rev Drug Discov* 2016;15:53–70.
39 Bronte V, Chappell DB, Apolloni E, et al. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumor inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol 1999;162:5728–37.

40 Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992;176:1693–702.

41 Heft J, Böttcher J, Chakravarty P, et al. GM-CSF mouse bone marrow cultures comprise a heterogeneous population of CD11c(+)MHCI(+) macrophages and dendritic cells. Immunity 2015;42:1197–211.

42 Yan W-L, Shen K-Y, Tien C-Y, et al. Recent progress in GM-CSF-based cancer immunotherapy. Immunotherapy 2017;9:547–60.

43 Borello I, Parodi D. GM-CSF-based cellular vaccines: a review of the clinical experience. Cytokine Growth Factor Rev 2002;13:185–93.

44 Dranoff G, Jaffee E, Lazenby A, et al. Tumor rejection by transfer of tumorigenic cells that constitutively secrete murine granulocyte-macrophage colony-stimulating factor. Proc Natl Acad Sci U S A 1993;90:5339–43.

45 Louis C, Cook AD, Lacey D, et al. Secretion of GM-CSF by tumors inhibits anti-tumor immunity. Proc Natl Acad Sci U S A 2009;106:5367–72.

46 Saxovici C, Mujagic Z, Mujanovic-Mustedanagic J, et al. Interleukin 13 expression in the primary breast cancer tumour tissue. Breast Cancers Res 2017;25:523–33.

47 Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen to naive T cells by antigen-presenting cells. J Exp Med 1994;179:1185–92.

48 Bhattacharya P, Budnick I, Singh M, et al. Dual role of GM-CSF as a pro-inflammatory and a regulatory cytokine: implications for immune therapy. J Interferon Cytokine Res 2015;35:585–99.

49 Gobbi D, Delgoffe GM. Leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 2007;110:4319–30.

50 Lacey DC, Achuthan A, Fleetwood AJ, et al. Defining GM-CSF- and macrophage-CSF-dependent macrophage responses by in vitro models. J Exp Med 2012;209:18572–65.

51 Colegio OR, Chu N-Q, Szabo AL, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 2014;513:599–603.

52 Zhang L, Li Z, Skrzypczyńska KM, et al. Single-cell analyses inform mechanisms of Myeloid-Targeted therapies in colon cancer. Cell 2020;181:e29:442–59.

53 Sidhu S, Lanzavecchia A. Efficient presentation of soluble antigen by dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994;179:1185–92.

54 Junthila IS. Tuning the cytokine responses: an update on Interleukin-12 and Interleukin-23. Cytokine Res 2014;60:1879–90.

55 Martínez FO, Helming L, Milde R, et al. Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences. Blood 2013;121:e57–69.

56 Rames G, Van den Bergh R, De Baetselier P, et al. Arginase-1 and Ym1 are markers for murine, but not human, alternatively activated myeloid cells. J Immunol 2005;174:6561–2.

57 Zilionis R, Engblom C, Pfirscinke C, et al. Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species. Immunity 2019;50:e10:1317–34.

58 Moganti K, Li F, Schmuttermaier C, et al. Hyperglycemia induces mixed M1/M2 cytokine profile in primary human macrophage-derived macrophages. Immunobiology 2017;222:952–9.

59 Chevrier S, Levine JH, Zanotelli VRT, et al. An immune atlas of clear cell renal cell carcinoma. Cell 2017;169:e18:736–49.

60 Azizi E, Carr AJ, Pilats G, et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell 2019;178:1481–1494.

61 Müller S, Kohanbash G, Liu SJ, et al. Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. Genome Biol 2017;18:234.

62 Mitsu K, Kam' ona R, Rylance J, et al. Human alveolar macrophages predominately express combined classical M1 and M2 surface markers in steady state. Respir Res 2018;19:66.

63 Chen YC, Shi W, Shi J-J, et al. Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective. J Cancer Immunol Oncol 2022;11:1481–1486.

64 Shi R, Chai Y, Duan X, et al. The identification of a CD47-blocking “hotspot” and design of a CD47/PD-L1 dual-specific antibody with limited hemagglutination. Signal Transduct Target Ther 2020;5:16.

65 Egle D, Meine V, Torres L, et al. Selective blockade of the ubiquitous checkpoint receptor CD47 is enabled by dual-targeting bispecific antibodies. Mol Ther 2017;25:523–33.

66 Liu B, Guo H, Xu J, et al. Generation of large numbers of granulocyte/macrophage colony-stimulating factor by tumors inhibits anti-tumor immunity. Proc Natl Acad Sci U S A 2009;106:5367–72.

67 Heft J, Böttcher J, Chakravarty P, et al. GM-CSF Mouse Bone Marrow Cultures Comprise a Heterogeneous Population of CD11c(+)MHCI(+) Macrophages and Dendritic Cells. Immunity 2015;42:1197–211.